|
Market Closed -
OTC Markets
02:29:50 19/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.1451 USD | -0.68% |
|
-13.84% | -36.57% |
Company Valuation: Northwest Biotherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Market Cap 1 | 364 | 358.4 | 258.9 | - |
| Change | - | -1.53% | -27.76% | - |
| Enterprise Value (EV) 1 | 364 | 358.4 | 355 | 383.8 |
| Change | - | -1.53% | -0.95% | 8.13% |
| P/E | -3.92x | -5.72x | - | - |
| PBR | - | - | - | - |
| PEG | - | 0.1x | - | - |
| Capitalization / Revenue | - | - | - | 6.65x |
| EV / Revenue | - | - | - | 9.86x |
| EV / EBITDA | - | - | - | - |
| EV / EBIT | - | - | -5.27x | -8.1x |
| EV / FCF | - | - | -6.96x | -9.42x |
| FCF Yield | - | - | -14.4% | -10.6% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -0.07 | -0.04 | - | - |
| Distribution rate | - | - | - | - |
| Net sales 1 | - | - | - | 38.93 |
| EBITDA | - | - | - | - |
| EBIT 1 | - | - | -67.3 | -47.4 |
| Net income | -85.19 | -61.48 | - | - |
| Net Debt 1 | - | - | 96.08 | 124.9 |
| Reference price 2 | 0.2748 | 0.2288 | 0.1451 | 0.1451 |
| Nbr of stocks (in thousands) | 13,24,666 | 15,66,728 | 17,84,345 | - |
| Announcement Date | 31/03/25 | 15/04/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 26Cr | ||
| 17.32x | 6.64x | 12.72x | 1.72% | 6.64TCr | ||
| 31.83x | 8.5x | 28.08x | 0.07% | 5.89TCr | ||
| 38.41x | 6.84x | 20.46x | 0.85% | 5.52TCr | ||
| 44.35x | 6.2x | 29.52x | -.--% | 4.72TCr | ||
| 33.62x | 3.22x | 13.9x | -.--% | 4.25TCr | ||
| 35.98x | 8.9x | 23.21x | 0.36% | 3.64TCr | ||
| -19.28x | 55.7x | -21.11x | -.--% | 3.52TCr | ||
| 41.59x | 8.02x | 26.91x | -.--% | 3.27TCr | ||
| -74.36x | 14.09x | -75.73x | -.--% | 2.67TCr | ||
| Average | 16.61x | 13.12x | 6.44x | 0.33% | 4TCr | |
| Weighted average by Cap. | 21.61x | 11.64x | 11.39x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- NWBO Stock
- Valuation Northwest Biotherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















